Takeda Buys Out Chinese Venture, Gains Flexibility In Decision-making For Commercial Expansion
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda currently posts only limited sales in China, but the company hopes that the full acquisition of its Chinese joint venture Tianjin Takeda will give the company more flexibility and speed in making business decisions to expand its presence in China
You may also be interested in...
Takeda Expands Abroad While Finding Its Way In Its Home Market
TOKYO - Takeda Pharmaceutical Co. Ltd. made a number of moves this week to expand its presence in Europe and China, including licensing Dainippon Sumitomo Co. Ltd.'s antipsychotic agent lurasidone in 26 EU member states and committing to more than triple its sales reps in China by 2015. But in Japan, Takeda and other pharma still grapple with assessing how the Tohoku earthquake has changed the Japanese market
Takeda Expands Abroad While Finding Its Way In Its Home Market
TOKYO - Takeda Pharmaceutical Co. Ltd. made a number of moves this week to expand its presence in Europe and China, including licensing Dainippon Sumitomo Co. Ltd.'s antipsychotic agent lurasidone in 26 EU member states and committing to more than triple its sales reps in China by 2015. But in Japan, Takeda and other pharma still grapple with assessing how the Tohoku earthquake has changed the Japanese market
Takeda Expands Abroad While Finding Its Way In Its Home Market
Takeda announces cross-licensing deals with Dainippon Sumitomo in a rights swap in Europe and Japan that involves ceftaroline and lurasidone.